Open AccessSARS-CoV-2 neutralizing antibody development strategies
Author(s) -
Bertan Koray Balcıoğlu,
Melis Denizci Öncü,
Hasan Ümit Öztürk,
Fatıma Yücel,
Filiz Kaya,
Müge Serhatlı,
Hivda Polat,
Şaban Teki̇n,
Aylin Özdemir Bahadır
Publication year - 2020
Publication title -
turkish journal of biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.323
H-Index - 38
eISSN - 1303-6092
pISSN - 1300-0152
DOI - 10.3906/biy-2005-91
Subject(s) - virology , antibody , pandemic , neutralizing antibody , biology , covid-19 , virus , coronavirus , neutralization , transmission (telecommunications) , viral entry , immunology , disease , medicine , infectious disease (medical specialty) , viral replication , electrical engineering , engineering
In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.